MOC

The 'Gulf Stream' will not collapse in 2025: What the alarmist headlines got wrong

Retrieved on: 
fredag, augusti 4, 2023

“Be very worried: Gulf Stream collapse could spark global chaos by 2025” announced the New York Post.

Key Points: 
  • “Be very worried: Gulf Stream collapse could spark global chaos by 2025” announced the New York Post.
  • This latest alarmist rhetoric provides a textbook example of how not to communicate climate science.
  • These headlines do nothing to raise public awareness, let alone influence public policy to support climate solutions.

We see the world we describe

    • It is well known that climate anxiety is fuelled by media messaging about the looming climate crisis.
    • This is causing many to simply shut down and give up — believing we are all doomed and there is nothing anyone can do about it.
    • This is also not the first time such headlines have emerged.

The currents are not collapsing (anytime soon)

    • The latest series of alarmist headlines may not have fixated on an impending ice age, but they still suggest the Atlantic meridional overturning circulation could collapse by 2025.
    • This is an outrageous claim at best and a completely irresponsible pronouncement at worst.
    • The Intergovernmental Panel on Climate Change has been assessing the likelihood of a cessation of deep-water formation in the North Atlantic for decades.
    • Other assessments, including the National Academy of Sciences Abrupt Impacts of Climate Change: Anticipating Surprises, published in 2013, also reached similar conclusions.

Understanding climate optimism

    • Ritchie persuasively argued that more people located in the green “optimistic and changeable” box are what is needed to advance climate solutions.
    • More importantly, rather than instilling a sense of optimism that global warming is a solvable problem, the extreme behaviour (fear mongering or civil disobedience) of the “pessimistic changeable” group (such as many within the Extinction Rebellion movement), often does nothing more than drive the public towards the “pessimistic not changeable” group.

A responsibility to communicate, responsibly

    • This is only amplified in situations where scientists make statements where creative licence is taken with speculative possibilities.
    • Climate scientists have agency in the advancement of climate solutions, and with that agency comes a responsibility to avoid sensationalism.

The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch

Retrieved on: 
måndag, juli 24, 2023

The first pulmonary sarcoidosis patients in this Phase II study are scheduled to begin receiving treatment in Q4 2O23.

Key Points: 
  • The first pulmonary sarcoidosis patients in this Phase II study are scheduled to begin receiving treatment in Q4 2O23.
  • This marks the beginning of a new chapter in the development of our flagship project, as we enter human proof-of-concept studies and begin treating pulmonary sarcoidosis patients with OATD-01.
  • In the coming weeks we are also planning to file for approval of phase II clinical trials with the European Medicines Agency (EMA).
  • That would make it possible for us to begin testing OATD-01 in the European Union – including Poland.

Molecure completes successful Secondary Public Offering (SPO) of approximately PLN 50 million (USD 12 million) with proceeds to be used to fund and build a first in class, sustainable pipeline of breakthrough therapies

Retrieved on: 
fredag, juli 21, 2023

The issue price was set at PLN 18, bringing the gross value of the offering to approximately PLN 50 million.

Key Points: 
  • The issue price was set at PLN 18, bringing the gross value of the offering to approximately PLN 50 million.
  • We would like to thank all investors for participating in the offering and for the trust they have placed in Molecure.
  • Considering the current market conditions, we view the execution of the share issue as a remarkable achievement.
  • Molecure estimates that the capital expenditure associated with the strategy from mid-2023 to the end of 2025 will amount to approximately PLN 250 million.

Molecure Files an Investigational New Drug (IND) application for lead clinical candidate OATD-01 with U.S. FDA ahead of a planned Phase 2 pulmonary sarcoidosis study

Retrieved on: 
fredag, juni 23, 2023

Clearance of the IND would allow Molecure to begin an international Phase 2 proof of concept study to evaluate OATD-01 for the treatment of pulmonary sarcoidosis.

Key Points: 
  • Clearance of the IND would allow Molecure to begin an international Phase 2 proof of concept study to evaluate OATD-01 for the treatment of pulmonary sarcoidosis.
  • “Today’s IND filing is another landmark milestone for Molecure and its lead product OATD-01” said Molecure CEO Marcin Szumowski.
  • We anticipate beginning our Phase 2 trial in patients in the US and EU in the fourth quarter of this year.
  • The results of this double-blinded study will be available once the study is complete, expected in H1 2025.

Governments of Canada and the United Kingdom advance partnership in biomanufacturing and quantum science

Retrieved on: 
torsdag, juni 8, 2023

This collaboration will also build upon past and current joint biomanufacturing activities, notably through the National Research Council of Canada (NRC).

Key Points: 
  • This collaboration will also build upon past and current joint biomanufacturing activities, notably through the National Research Council of Canada (NRC).
  • Supported by a $32 million jointly administered fund, this new partnership will advance, among other things, collaborative science, research and development, and industrial development.
  • Funding under the biomanufacturing MOC will be jointly administered by the NRC in Canada and Innovate UK in the United Kingdom.
  • In a joint statement, ministers Champagne and Freeman also committed to increasing collaboration in quantum science and technology.

Walker Hayes, Jax and More Join Musicians on Call and Men’s Wearhouse in Creating Unforgettable Prom Memories for Teens in Pediatric Hospitals

Retrieved on: 
torsdag, juni 1, 2023

National brands and popular recording artists have partnered with the organization to create a unique Prom experience exclusively for children’s hospitals nationwide.

Key Points: 
  • National brands and popular recording artists have partnered with the organization to create a unique Prom experience exclusively for children’s hospitals nationwide.
  • The concert will be available for pediatric patients nationwide to enjoy in their hospital rooms throughout the Prom season.
  • "At Men's Wearhouse, we believe that every teenager deserves to have an unforgettable Prom.
  • For more information on the Musicians On Call Prom Presented by Men’s Wearhouse, visit www.musiciansoncall.org .

NewLink and Dubai Chambers Forge Strategic Partnership to Support Bilateral Innovation Exchange and Collaboration

Retrieved on: 
lördag, maj 27, 2023

Under the partnership, Dubai Chambers will support the NewLink and companies introduced by NewLink with necessary information and assistance in registering commercial licenses in Dubai.

Key Points: 
  • Under the partnership, Dubai Chambers will support the NewLink and companies introduced by NewLink with necessary information and assistance in registering commercial licenses in Dubai.
  • By streamlining administrative procedures and providing essential guidance, Dubai Chambers hopes to establish a favorable business environment for global enterprises as they establish their presence in Dubai market.
  • As a trusted advisor and partner, NewLink will also work closely with Dubai Chambers to navigate the complexities of the China market.
  • In addition, NewLink and Dubai Chambers discussed opportunities to showcase China’s green and cleantech technologies during the upcoming COP28 UAE scheduled later this year.

S&P Global Commodity Insights Launches India's First Price Assessment for R-PET

Retrieved on: 
torsdag, april 13, 2023

SINGAPORE, April 13, 2023 /PRNewswire/ -- S&P Global Commodity Insights, the leading independent provider of information, analysis and benchmark prices for the commodities and energy markets, announced on April 3 the launch of India's first price assessment by Platts for recycled polyethylene terephthalate flakes (R-PET) to bring greater transparency to pricing, especially with recycled plastics demand rising amidst global energy transition efforts. The launch of the new free-on-board (FOB) India R-PET price assessment further augments Platts' pre-existing suite of R-PET offerings, which includes price assessments in Europe, U.S. and Southeast Asia.

Key Points: 
  • The launch of the new free-on-board (FOB) India R-PET price assessment further augments Platts' pre-existing suite of R-PET offerings, which includes price assessments in Europe, U.S. and Southeast Asia.
  • Vanessa Ronsisvalle, regional pricing director, Asia petrochemicals, S&P Global Commodity Insights, said: "The new Platts FOB India R-PET price assessment will help meet a growing need from market participants for high-quality, transparent pricing information for this fast-developing export market in Asia.
  • We believe the marketplace will find Platts pricing information of critical value to the development of the Indian recycled plastics market, as it becomes increasingly commoditized."
  • The new assessments will be underpinned by the rigorous Platts Market-On-Close (MOC) price assessment methodology, which produces a daily end-of-day value that reflects prices as determined by buyers and sellers in the open physical markets.

Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress

Retrieved on: 
torsdag, mars 30, 2023

“Molecure has made significant progress over 2022, becoming a clinical stage biotechnology company preparing our two most advanced assets to start multi-center phase I and phase II studies respectively” said Marcin Szumowski, CEO and President of the Management Board of Molecure.

Key Points: 
  • “Molecure has made significant progress over 2022, becoming a clinical stage biotechnology company preparing our two most advanced assets to start multi-center phase I and phase II studies respectively” said Marcin Szumowski, CEO and President of the Management Board of Molecure.
  • In recent weeks, we achieved an important milestone dosing the first cancer patient in a Phase I study with OATD-02, the first and only dual arginase inhibitor.
  • The Company's full year presentation to investors will be held on April 5, 2023 at 2:00 PM (CET) in an online meeting.
  • In 2022, Molecure announced a new name and brand identity.

Penn Radiology Division of Musculoskeletal Radiology Invests in Medality to Make Training More Productive

Retrieved on: 
torsdag, mars 30, 2023

CINCINNATI, March 30, 2023 /PRNewswire-PRWeb/ -- Today, the Penn Radiology Division of Musculoskeletal Radiology (Penn MSK Radiology), announced that it has invested in Medality, formerly MRI Online, to help make training more productive for radiology residents and fellows. The Penn MSK Radiology Division will integrate the Medality case-based learning platform into their MSK curriculum to support trainees during their rotations.

Key Points: 
  • CINCINNATI, March 30, 2023 /PRNewswire-PRWeb/ -- Today, the Penn Radiology Division of Musculoskeletal Radiology (Penn MSK Radiology), announced that it has invested in Medality, formerly MRI Online, to help make training more productive for radiology residents and fellows.
  • The Penn MSK Radiology Division will integrate the Medality case-based learning platform into their MSK curriculum to support trainees during their rotations.
  • The partnership with Medality demonstrates Penn MSK Radiology Division's commitment to providing the most advanced and comprehensive educational resources for its radiology residents and fellows.
  • "Penn MSK Radiology is proud to offer outstanding educational opportunities and training to our radiology residents and fellows.